Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Radiotherapy + SOX + PD-1 Inhibitor vs SOX + PD-1 Inhibitor in Unresectable Advanced Gastric Cancer
ChiCTR2500110826Phase 2Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin and tegafur in gastric cancer (GC) (2 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: R0 resection rate. Started Oct 2025; status: recruiting.
02
Drugs
oxaliplatintegafur
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2500110826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110826.